GlaxoSmithKline News and Research

RSS

Sanofi-Aventis, GlaxoSmithKline will donate influenza vaccines to WHO

The drugmaker Sanofi-Aventis will donate millions of doses of a vaccine that offers protection against the H1N1 (swine flu) virus to the WHO once the vaccine is ready, the company's chief executive officer announced Tuesday, Reuters reports (Elsner, Reuters, 6/17).

18 Jun 2009

GlaxoSmithKline to cut some drug costs in emerging markets

GlaxoSmithKline (GSK) plans to decrease the prices of many of its leading medicines in emerging markets following the success of a pilot program in the Philippines, Andrew Witty, GSK's chief executive, said, Financial Times reports. Witty said the price cuts are part of an effort to diversify and expand globally.

15 Jun 2009

Medical industry showers Department of Defense with free travel

The health care industry funded "8,700 trips by Department of Defense personnel" from 1998 to 2007, at a cost of more than $10 million, the Center for Public Integrity reports.

10 Jun 2009

GlaxoSmithKline opens pneumonia vaccine plant In Singapore

Drug maker GlaxoSmithKline (GSK) on Tuesday opened a $600 million plant in Singapore that is slated to begin producing vaccines to fight pneumonia-causing bacteria in 2011, Reuters reports.

10 Jun 2009

WHO recommends global use of rotavirus vaccines - can protect millions of children from diarrhoeal diseaseas

The World Health Organization (WHO) has recommended that rotavirus vaccination be included in all national immunization programmes to provide protection against a virus that is responsible for more than 500,000 diarrhoeal deaths and 2 million hospitalizations every year among children. More than 85% of these deaths occur in developing countries in Africa and Asia. This new policy will help ensure access to rotavirus vaccines in the world's poorest countries.

5 Jun 2009

WHO closer to declaring H1N1 flu outbreak a pandemic

The WHO on Tuesday said it was "getting closer" to declaring the H1N1 (swine) flu outbreak to be a pandemic, as the virus continues to spread to people outside of North America, and in populations "as far apart as Britain, Spain, Japan, Chile and Australia," the AP/Washington Post reports (Jordans, AP/Washington Post, 6/2).

3 Jun 2009

Cancer Research UK and Glaxosmithkline join forces to trial new anti-cancer drug

Cancer Research UK and Cancer Research Technology (CRT) today announced they will begin a phase I clinical trial of an anti-cancer drug from GlaxoSmithKline (GSK).

19 May 2009

Oxford BioTherapeutics and GSK form alliance to develop cancer therapeutic antibodies

Oxford BioTherapeutics (OBT) today announced a strategic alliance with GlaxoSmithKline to discover, develop and commercialise novel, therapeutic antibodies for the treatment of primary, metastatic and recurring forms of cancer.

18 May 2009

Swine flu preoccupies world health leaders

It is expected that the upcoming World Health Organisation's (WHO) annual assembly will be dominated this year by the emergence and spread of the new influenza virus H1N1 (swine flu).

14 May 2009

GlaxoSmithKline to acquire 16% shareholding in Aspen Pharmacare

GlaxoSmithKline plc (GSK) today announced that it has agreed to extend its strategic relationship with Aspen Pharmacare Holdings Limited (Aspen) and to acquire a 16% shareholding in the South African based pharmaceuticals company.

12 May 2009

Participants in antidepressant drug trials are atypical patients

One reason antidepressant medication treatments do not work as well in real life as they do in clinical studies could be the limited type of study participants selected, researchers at UT Southwestern Medical Center have found.

12 May 2009

GSK to divest U.S. rights for Wellbutrin XL to Biovail

GlaxoSmithKline has announced that it has entered into an agreement to divest full commercial rights to Wellbutrin XL in the United States to Biovail International Laboratories SRL, a subsidiary of Biovail Corporation, for $510 million (euro 340 million). The agreement is subject to Hart-Scott-Rodino regulatory clearance in the United States.

6 May 2009

New antidepressants might be no more effective than the best existing drugs

The reviews suggest that sertraline - sold under the brand name Zoloft since 1991- could be the best initial choice of antidepressant in people with acute major depression. The generic formulation produced the best balance of effectiveness, tolerability and purchase price, the authors say.

5 May 2009

GlaxoSmithKline and Pfizer team up to form HIV company

Pharmaceutical companies GlaxoSmithKline and Pfizer today announced an "innovative agreement" to pool their HIV assets creating a new world-leading, specialist HIV company.

16 Apr 2009

Colon cancer shuts down receptor that could shut it down

Though a high-fiber diet has long been considered good for you and beneficial in staving off colon cancer, Medical College of Georgia researchers have discovered a reason why: roughage activates a receptor with cancer-killing potential.

13 Apr 2009

New small molecule approach to Alzheimer's disease treatment

New therapeutic approaches in Alzheimer's disease are urgently needed.

13 Apr 2009

Experimental vaccine shows promise for the treatment of early lung cancer

An experimental vaccine that triggers the patient's immune system to identify and attack specific tumor cells is showing new promise for the treatment of early lung cancer.

6 Apr 2009

FDA warns 14 pharmaceutical companies about short internet ads lacking risk information

FDA has warned 14 major pharmaceutical firms about brief Internet advertisements that could have misled patients because they did not include information about health risks related to the drugs, according to letters posted to the agency's Web site Friday, the Wall Street Journal reports.

6 Apr 2009

Schizophrenia could be caused by faulty signalling in the brain

In the biggest study of its kind, scientists looking in detail at brain samples donated by people with the condition have identified 49 genes that work differently in the brains of schizophrenia patients compared to controls.

2 Apr 2009

NEJM Letters respond to recent studies on malaria vaccines, treatments

The New England Journal of Medicine in its March 19 issue featured a letter to the editor written in response to a study published in its Dec. 11 issue reporting the results of the RTS,S/AS01E malaria vaccine trial.

23 Mar 2009